Top

Published in:

Open Access 01-09-2016 | Original Article

Successful management of chronic disseminated candidiasis in hematologic patients treated with high-dose liposomal amphotericin B: a retrospective study of the SEIFEM registry

Authors: Roberta Della Pepa, M. Picardi, F. Sorà, M. Stamouli, A. Busca, A. Candoni, M. Delia, R. Fanci, V. Perriello, M. Zancanella, A. Nosari, P. Salutari, F. Marchesi, F. Pane, L. Pagano, on behalf of the SEIFEM group (Sorveglianza Epidemiologica Infezioni Fungine in Ematologia)

Published in: Supportive Care in Cancer | Issue 9/2016

Abstract

Purpose

Chronic disseminated candidiasis (CDC) is a complication of Candida infection in immunocompromised patients, involving the liver and spleen, and rarely other organs. The aim of the study is to identify the best antifungal drug for hematologic immunocompromised patients with CDC.

Methods

In this multicentric retrospective study, the charts of 20 patients with CDC following cytotoxic agent protocols for hematological malignancies, diagnosed from 2003 to 2013, were analyzed. The response to systemic antifungal therapy within 90 days from CDC diagnosis and the possible delay in chemotherapy plan, due to the infection, were evaluated.

Results

Six patients were treated with high-dose (HD; 5 mg/kg/daily) liposomal amphotericin B (L-AmB), whereas three received standard-dose (SD) L-AmB (3 mg/kg/daily). Azoles were given to six patients; the remaining five were treated with echinocandins. All patients treated with HD L-AmB (6/6—100 %) achieved complete resolution of CDC; one of them had to interrupt the chemotherapy program for the infection. In the SD L-AmB group, treatment failed in the 100 % of cases and one patient had to delay chemotherapy for the infection. Of the six patients who received azoles, two achieved complete resolution of the infection, four experienced treatment failure, and only three performed chemotherapy as planned. Echinocandins treatment resulted in complete resolution of the infection in 2/5 cases, partial response in 2/5 cases, and failure in one case. In this group, 3/5 patients completed chemotherapy as planned.

Conclusions

This study shows that HD L-AmB was particularly effective against CDC in hematologic patients, allowing most patients to continue cytotoxic agent program.

Beck-Sague C, Jarvis WR (1993) Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980–1990. National Nosocomial Infections Surveillance System. J Infect Dis 167(5):1247–1251CrossRefPubMed

Jarvis WR, Martone WJ, Suppl A (1992) Predominant pathogens in hospital infections. J Antimicrob Chemother 29:19–24CrossRefPubMed

Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, Bonini A, Chierichini A, Fanci R, Caramatti C, Invernizzi R, Mattei D, Mitra ME, Melillo L, Aversa F, Van Lint MT, Falcucci P, Valentini CG, Girmenia C, Nosari A (2006) The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91(8):1068–1075PubMed

Pagano L, Caira M, Rossi G, Tumbarello M, Fanci R, Garzia MG, Vianelli N, Filardi N, De Fabritiis P, Beltrame A, Musso M, Piccin A, Cuneo A, Cattaneo C, Aloisi T, Riva M, Rossi G, Salvadori U, Brugiatelli M, Sannicolo S, Morselli M, Bonini A, Viale P, Nosari A, Aversa F, Hema e-Chart Group I (2012) A prospective survey of febrile events in hematological malignancies. Ann Hematol 91(5):767–774. doi:10.1007/s00277-011-1373-2 CrossRefPubMed

Lehrnbecher T, Frank C, Engels K, Kriener S, Groll AH, Schwabe D (2010) Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 61(3):259–265. doi:10.1016/j.jinf.2010.06.018 CrossRefPubMed

Lewis RE, Cahyame-Zuniga L, Leventakos K, Chamilos G, Ben-Ami R, Tamboli P, Tarrand J, Bodey GP, Luna M, Kontoyiannis DP (2013) Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses 56(6):638–645. doi:10.1111/myc.12081 CrossRefPubMed

Jarvis WR (1995) Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 20(6):1526–1530CrossRefPubMed

Perduca M, Marangoni E, Guanziroli A, Romero E, Filice G (1995) Fungaemia in hospitalized patients. Mycoses 38(9–10):385–387CrossRefPubMed

Nosari AM, Caira M, Pioltelli ML, Fanci R, Bonini A, Cattaneo C, Castagnola C, Capalbo SF, De Fabritiis P, Mettivier V, Morselli M, Pastore D, Aversa F, Rossi G, Pagano L, Hema e-Chart Group I (2013) Hema e-Chart registry of invasive fungal infections in haematological patients: improved outcome in recent years in mould infections. Clin Microbiol Infect 19(8):757–762. doi:10.1111/1469-0691.12014 CrossRefPubMed

10.

Masood A, Sallah S (2005) Chronic disseminated candidiasis in patients with acute leukemia: emphasis on diagnostic definition and treatment. Leuk Res 29(5):493–501. doi:10.1016/j.leukres.2004.10.003 CrossRefPubMed

11.

De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Munoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE, European Organization for R, Treatment of Cancer/Invasive Fungal Infections Cooperative G, National Institute of A, Infectious Diseases Mycoses Study Group Consensus G (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46(12):1813–1821. doi:10.1086/588660 CrossRefPubMedPubMedCentral

12.

Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, Walsh TJ, Maertens J, Patterson TF, Perfect JR, Dupont B, Wingard JR, Calandra T, Kauffman CA, Graybill JR, Baden LR, Pappas PG, Bennett JE, Kontoyiannis DP, Cordonnier C, Viviani MA, Bille J, Almyroudis NG, Wheat LJ, Graninger W, Bow EJ, Holland SM, Kullberg BJ, Dismukes WE, De Pauw BE (2008) Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 47(5):674–683. doi:10.1086/590566 CrossRefPubMedPubMedCentral

13.

Kaplan ELM, P (1958) Nonparametric estimation from incomplete observations. J Amer Statist Assn 53:457–481CrossRef

14.

Kaplan EL (1983) This week’s citation classic. Current Contents 24:14

15.

Blade J, Lopez-Guillermo A, Rozman C, Granena A, Bruguera M, Bordas J, Cervantes F, Carreras E, Sierra J, Montserrat E (1992) Chronic systemic candidiasis in acute leukemia. Ann Hematol 64(5):240–244CrossRefPubMed

16.

Pagano L, Mele L, Fianchi L, Melillo L, Martino B, D’Antonio D, Tosti ME, Posteraro B, Sanguinetti M, Trape G, Equitani F, Carotenuto M, Leone G (2002) Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes. Haematologica 87(5):535–541PubMed

17.

Ellis M, Frampton C, Joseph J, Alizadeh H, Kristensen J, Hauggaard A, Shammas F (2006) An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy. J Med Microbiol 55(Pt 10):1357–1365. doi:10.1099/jmm.0.46452-0 CrossRefPubMed

18.

De Castro N, Mazoyer E, Porcher R, Raffoux E, Suarez F, Ribaud P, Lortholary O, Molina JM (2012) Hepatosplenic candidiasis in the era of new antifungal drugs: a study in Paris 2000–2007. Clin Microbiol Infect 18(6):E185–187. doi:10.1111/j.1469-0691.2012.03819.x CrossRefPubMed

19.

Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Diseases Society of A (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48(5):503–535. doi:10.1086/596757 CrossRefPubMed

20.

Chakraborty KK, Naik SR (2000) In situ liposomal preparation containing amphotericin B: related toxicity and tissue disposition studies. Pharm Dev Technol 5(4):543–553. doi:10.1081/PDT-100102037 CrossRefPubMed

21.

Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Florl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ, Group EFIS (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl 7):19–37. doi:10.1111/1469-0691.12039 CrossRefPubMed

22.

Mousset S, Buchheidt D, Heinz W, Ruhnke M, Cornely OA, Egerer G, Kruger W, Link H, Neumann S, Ostermann H, Panse J, Penack O, Rieger C, Schmidt-Hieber M, Silling G, Sudhoff T, Ullmann AJ, Wolf HH, Maschmeyer G, Bohme A (2014) Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 93(1):13–32. doi:10.1007/s00277-013-1867-1 CrossRefPubMed

23.

Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, Heussel CP, Lortholary O, Rieger C, Boehme A, Aoun M, Horst HA, Thiebaut A, Ruhnke M, Reichert D, Vianelli N, Krause SW, Olavarria E, Herbrecht R, AmBiLoad Trial Study G (2007) Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44(10):1289–1297. doi:10.1086/514341 CrossRefPubMed

24.

Adler-Moore JP, Gangneux JP, Pappas PG (2016) Comparison between liposomal formulations of amphotericin B. Med Mycol. doi:10.1093/mmy/myv111 PubMed

25.

Ellis M, Spence D, de Pauw B, Meunier F, Marinus A, Collette L, Sylvester R, Meis J, Boogaerts M, Selleslag D, Krcmery V, von Sinner W, MacDonald P, Doyen C, Vandercam B (1998) An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 27(6):1406–1412CrossRefPubMed

26.

Vogelsinger H, Weiler S, Djanani A, Kountchev J, Bellmann-Weiler R, Wiedermann CJ, Bellmann R (2006) Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrob Chemother 57(6):1153–1160. doi:10.1093/jac/dkl141 CrossRefPubMed

Title: Successful management of chronic disseminated candidiasis in hematologic patients treated with high-dose liposomal amphotericin B: a retrospective study of the SEIFEM registry
Authors: Roberta Della Pepa
M. Picardi
F. Sorà
M. Stamouli
A. Busca
A. Candoni
M. Delia
R. Fanci
V. Perriello
M. Zancanella
A. Nosari
P. Salutari
F. Marchesi
F. Pane
L. Pagano
on behalf of the SEIFEM group (Sorveglianza Epidemiologica Infezioni Fungine in Ematologia)
Publication date: 01-09-2016
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 9/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-016-3208-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2016

Bisphosphonate-related osteonecrosis of the jaw: a review of the potential efficacy of low-level laser therapy

The Italian version of the FAMCARE scale: a validation study

Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden

Quality of life and symptom burden in patients with metastatic breast cancer

Oncologists’ experiences of discussing complementary and alternative treatment options with their cancer patients. A qualitative analysis

Hyponatremia in solid-tumor cancer patients: uncertainty regarding the use of vaptans

Keynote webinar | Spotlight on antibody–drug conjugates in cancer